Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

By afschroeder • October 20, 2025

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Oct 19:101200JCO2502023. doi: 10.1200/JCO-25-02023. Epub ahead of print. PMID: 41109959.

Tags: binimetinib, BRAF, Encorafenib, Hematology/Oncology, Non-small cell lung cancer, Publications

Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy

Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid[...]

Cumulative burden of depression and domain-specific cognitive impairment over time in the women’s interagency HIV study: A marginal structural model approach

Tejera CH, Duggal P, Diaz M, Topper E, Gustafson D, Jamieson BD, Maki PM, Sharma A, Spence AB, Weber KM, Weinstein AM, Jones DL, Fazeli[...]

Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis

Young AC, Andréasson K, Labus J, Matulionis N, Jacobs JP, Christofk H, Volkmann ER. Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis.[...]